MCID: LVR013
MIFTS: 76

Liver Disease

Categories: Gastrointestinal diseases, Rare diseases, Liver diseases, Genetic diseases, Metabolic diseases

Aliases & Classifications for Liver Disease

Summaries for Liver Disease

MedlinePlus : 40 Your liver is the largest organ inside your body. It helps your body digest food, store energy, and remove poisons. There are many kinds of liver diseases: Diseases caused by viruses, such as hepatitis A, hepatitis B, and hepatitis C Diseases caused by drugs, poisons, or too much alcohol. Examples include fatty liver disease and cirrhosis. Liver cancer Inherited diseases, such as hemochromatosis and Wilson disease Symptoms of liver disease can vary, but they often include swelling of the abdomen and legs, bruising easily, changes in the color of your stool and urine, and jaundice, or yellowing of the skin and eyes. Sometimes there are no symptoms. Tests such as imaging tests and liver function tests can check for liver damage and help to diagnose liver diseases.

MalaCards based summary : Liver Disease, also known as liver diseases, is related to fatty liver disease and nonalcoholic steatohepatitis, and has symptoms including abnormal bruising, gastrointestinal gas and digestive system symptom. An important gene associated with Liver Disease is SERPINA1 (Serpin Family A Member 1), and among its related pathways/superpathways are Metabolism and Selenium Micronutrient Network. The drugs Amlodipine and Angiotensin II have been mentioned in the context of this disorder. Affiliated tissues include liver, testes and kidney, and related phenotypes are homeostasis/metabolism and growth/size/body region

Wikipedia : 72 Liver disease (also called hepatic disease) is a type of damage to or disease of the... more...

Related Diseases for Liver Disease

Diseases in the Liver Disease family:

Liver Failure, Infantile, Transient Infantile Liver Failure Syndrome 1
Infantile Liver Failure Syndrome 2 Acute Liver Failure

Diseases related to Liver Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 550)
# Related Disease Score Top Affiliating Genes
1 fatty liver disease 34.0 ADIPOQ CYP2E1 GGT1 GPT INS KRT18
2 nonalcoholic steatohepatitis 33.1 ADIPOQ F2 GPT INS KRT18 PNPLA3
3 alcoholic hepatitis 33.0 ALB CYP2E1 F2 GPT KRT18 SLC17A5
4 wilson disease 32.5 ALB F2 GPT
5 hepatic vascular disease 32.3 AFP ALB F2
6 cholangitis, primary sclerosing 32.3 ABCB4 DLAT GGT1 GPT
7 cholestasis, progressive familial intrahepatic, 1 32.2 ABCB11 ABCB4 GGT1
8 sclerosing cholangitis 32.2 ABCB11 ABCB4 ALB TNF
9 hepatitis c 32.1 AFP GGT1 GPT TNF
10 hepatic encephalopathy 32.0 ALB F2 GPT SLC17A5 TNF
11 acute liver failure 31.8 ALB F2 GPT HGF SLC17A5
12 cholestasis, progressive familial intrahepatic, 2 31.6 ABCB11 ABCB4
13 cholestasis, progressive familial intrahepatic, 3 31.5 ABCB11 ABCB4
14 autoimmune hepatitis 31.5 DLAT F2 GGT1 GPT
15 hepatitis 31.4 AFP F2 GGT1 GPT SLC17A5 TNF
16 body mass index quantitative trait locus 11 31.2 ADIPOQ CYP2E1 GGT1 GPT INS PNPLA3
17 alcoholic liver cirrhosis 31.0 ALB CYP2E1 F2 PNPLA3 SLC17A5 TNF
18 portal hypertension 30.9 ALB F2 GPT TNF
19 hepatic coma 30.7 ALB F2 GPT
20 hepatitis b 30.6 AFP ALB F2 GGT1 GPT SLC17A5
21 alcohol abuse 30.5 CYP2E1 GGT1 GPT SLC17A5
22 peritonitis 30.5 ALB F2 TNF
23 cholelithiasis 30.5 ABCB4 ALB GPT
24 cholestasis 30.5 ABCB11 ABCB4 F2 GGT1 GPT HSD3B7
25 morbid obesity 30.5 ADIPOQ ALB INS
26 sleep apnea 30.5 ADIPOQ INS TNF
27 apnea, obstructive sleep 30.5 ADIPOQ INS TNF
28 arteries, anomalies of 30.4 ADIPOQ ALB F2 INS TNF
29 intrahepatic cholestasis 30.3 ABCB11 ABCB4 ALB GGT1 HSD3B7 SLC17A5
30 biliary atresia 30.3 ALB GPT HGF
31 antipyrine metabolism 30.3 ALB F2
32 esophageal varix 30.2 AFP ALB F2
33 pyridoxine deficiency 30.2 GPT SLC17A5
34 hepatitis e 30.2 ALB F2 GPT TNF
35 hepatocellular carcinoma 30.2 AFP ALB CYP2E1 F2 FAH GGT1
36 cholangitis 30.2 ABCB11 ABCB4 ALB DLAT F2 GGT1
37 primary biliary cirrhosis 30.1 ABCB11 ABCB4 ALB DLAT F2 GGT1
38 hepatitis a 30.0 AFP ALB F2 GPT SERPINA1 TNF
39 kwashiorkor 30.0 ALB F2 GPT SLC17A5
40 bilirubin metabolic disorder 30.0 ALB F2 GGT1 GPT
41 inherited metabolic disorder 30.0 ADIPOQ INS PNPLA3 SERPINA1
42 protein-energy malnutrition 29.9 ALB GPT TNF
43 cholangiocarcinoma 29.9 AFP GGT1 HGF KRT18
44 viral hepatitis 29.9 AFP ALB F2 GGT1 GPT KRT18
45 heart disease 29.9 ADIPOQ ALB F2 INS TNF
46 schistosomiasis 29.8 ALB F2 TNF
47 obstructive jaundice 29.8 ALB F2 GGT1 GPT HGF SLC17A5
48 compartment syndrome 29.8 ALB F2 SLC17A5 TNF
49 eclampsia 29.8 ALB F2 TNF
50 liver cirrhosis 29.5 ADIPOQ AFP ALB CYP2E1 F2 GGT1

Comorbidity relations with Liver Disease via Phenotypic Disease Network (PDN):


Active Peptic Ulcer Disease Acute Cystitis
Acute Pancreatitis Deficiency Anemia
Familial Atrial Fibrillation Heart Disease
Hepatic Encephalopathy Ischemic Heart Disease
Protein-Energy Malnutrition

Graphical network of the top 20 diseases related to Liver Disease:



Diseases related to Liver Disease

Symptoms & Phenotypes for Liver Disease

UMLS symptoms related to Liver Disease:


abnormal bruising, gastrointestinal gas, digestive system symptom, liver tender, nausea and vomiting, icterus, hepatosplenomegaly, heartburn, dyspepsia, diarrhea, constipation, abdominal pain

MGI Mouse Phenotypes related to Liver Disease:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.13 TNF SLC17A5 FAH ABCB11 GGT1 ABCB4
2 growth/size/body region MP:0005378 10.1 TNF SLC17A5 F2 ABCB11 FAH GGT1
3 liver/biliary system MP:0005370 9.97 TNF FAH ABCB11 ABCB4 HGF ADIPOQ
4 mortality/aging MP:0010768 9.83 TNF F2 SLC17A5 FAH ABCB11 GGT1
5 neoplasm MP:0002006 9.17 TNF FAH ABCB4 ADIPOQ AFP ALB

Drugs & Therapeutics for Liver Disease

Drugs for Liver Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1268)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Amlodipine Approved Phase 4,Phase 1 88150-42-9 2162
2
Angiotensin II Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 68521-88-0, 4474-91-3, 11128-99-7 172198 65143
3
Perindopril Approved Phase 4 107133-36-8, 82834-16-0 107807
4
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
5
Ursodeoxycholic acid Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 128-13-2 31401
6
Entecavir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 142217-69-4 153941
7
Lamivudine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 134678-17-4 60825
8
Caspofungin Approved Phase 4 162808-62-0, 179463-17-3 2826718 468682
9
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 22916-47-8 4189
10
Morphine Approved, Investigational Phase 4,Phase 3,Phase 1 57-27-2 5288826
11
Emtricitabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 143491-57-0 60877
12
Adefovir Dipivoxil Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 142340-99-6 60871
13
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 104987-11-3 445643 439492
14
Ezetimibe Approved Phase 4,Phase 2,Phase 1 163222-33-1 150311
15
Orlistat Approved, Investigational Phase 4 96829-58-2 3034010
16
Magnesium oxide Approved Phase 4 1309-48-4 14792
17
Peginterferon alfa-2a Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 198153-51-4 5360545
18
Ribavirin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 36791-04-5 37542
19
Insulin Glargine Approved Phase 4,Phase 2 160337-95-1
20
Insulin-glulisine Approved Phase 4 207748-29-6
21
Zinc Approved, Investigational Phase 4,Phase 3,Phase 2 7440-66-6 32051 23994
22
Lactulose Approved Phase 4,Phase 3,Phase 2,Phase 1 4618-18-2 11333
23
Metformin Approved Phase 4,Phase 2,Phase 3,Phase 1 657-24-9 4091 14219
24
Liraglutide Approved Phase 4,Phase 3,Phase 2 204656-20-2 44147092
25
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2 1994-09-7, 94-09-7 2337
26
Telbivudine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 3424-98-4 159269
27
Nitazoxanide Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 55981-09-4 41684
28
Acamprosate Approved, Investigational Phase 4 77337-76-9 71158
29
Ethanol Approved Phase 4,Phase 2,Phase 3,Phase 1 64-17-5 702
30
Rifaximin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 80621-81-4 6436173
31
Erythromycin Approved, Investigational, Vet_approved Phase 4,Phase 1 114-07-8 12560
32
Simvastatin Approved Phase 4,Phase 3,Phase 2,Phase 1 79902-63-9 54454
33
Peginterferon alfa-2b Approved Phase 4,Phase 3,Phase 2,Phase 1 215647-85-1, 99210-65-8
34
Menthol Approved Phase 4,Phase 3,Phase 1,Phase 2 2216-51-5 16666
35
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 128794-94-5 5281078
36
Mycophenolic acid Approved Phase 4,Phase 3,Phase 1,Phase 2 24280-93-1 446541
37
Propranolol Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 525-66-6 4946
38
Nadolol Approved Phase 4,Phase 3 42200-33-9 39147
39
Carvedilol Approved, Investigational Phase 4,Phase 3 72956-09-3 2585
40
Spironolactone Approved Phase 4,Phase 2,Phase 3 1952-01-7, 52-01-7 5833
41
Losartan Approved Phase 4,Phase 3,Phase 2 114798-26-4 3961
42
Amoxicillin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 26787-78-0 33613 2171
43
Azithromycin Approved Phase 4,Phase 2 83905-01-5 53477736 447043 55185
44
Cefotaxime Approved Phase 4 63527-52-6 5742673 456256
45
Cefoxitin Approved Phase 4 35607-66-0 441199
46
Ciprofloxacin Approved, Investigational Phase 4,Phase 1,Early Phase 1 85721-33-1 2764
47
Imipenem Approved Phase 4 64221-86-9, 74431-23-5 104838
48
Vancomycin Approved Phase 4,Phase 3 1404-90-6 14969 441141
49 Nadroparin Approved, Investigational Phase 4,Phase 2,Phase 3 9041-08-1
50
Warfarin Approved Phase 4,Phase 3,Phase 2 81-81-2 54678486 6691

Interventional clinical trials:

(show top 50) (show all 7691)

# Name Status NCT ID Phase Drugs
1 Placebo Controlled Study Using Lovaza as Treatment for Non-Alcoholic Fatty Liver Disease Unknown status NCT00941642 Phase 4 Lovaza;placebo control
2 Perindopril and Telmisartan for the Treatment of Nonalcoholic Fatty Liver Disease Unknown status NCT02213224 Phase 4 Perindopril;Telmisartan;Amlodipine
3 The Effect Of Dual Treatment With L-Carnitine And Magnesium On Fatty Liver Unknown status NCT01956825 Phase 4
4 Efficacy and Safety of Ursodeoxycholic Acid (UDCA) Added to the DPP-4 Inhibitor in People With Type 2 Diabetes and Chronic Liver Diseases Unknown status NCT01337440 Phase 4 UDCA;Sitagliptin
5 Atorvastatin Versus Vitamin E in Treatment of Non-alcoholic Fatty Liver Disease Unknown status NCT01720719 Phase 4 atorvastatin;Vitamin E
6 Antiviral Therapy in Hepatitis B Virus (HBV)-Related Advanced Liver Disease Patients Unknown status NCT00823550 Phase 4 Entecavir;Lamivudine
7 Pharmacokinetics of Caspofungin After One Dose in Patients With Liver Failure Unknown status NCT01968395 Phase 4 Caspofungin 70 mg
8 The Orange-III Trial: Optimised Recovery With Movicol® Preoperatively Within an Enhanced Recovery Programme Unknown status NCT01429779 Phase 4 Movicol
9 Intravenous-Morphine and Glucagon-Usage Enhanced MR Cholangiography Unknown status NCT00155376 Phase 4 morphine and glucagon
10 Effect of Probiotics on Gut-Liver Axis of Alcoholic Hepatitis Unknown status NCT02335632 Phase 4 Probiotics (Lacidofil®);Placebo
11 Emtricitabine for Naive Child Chinese Chronic Hepatitis B Patients Unknown status NCT02327676 Phase 4 Emtricitabine
12 Emtricitabine for Naive Chinese Chronic Hepatitis B Patients Unknown status NCT02327663 Phase 4 Emtricitabine
13 A Study of Thymoglobulin and Tacrolimus in Liver Transplant Unknown status NCT00564538 Phase 4 anti-thymocyte globulin (rabbit);tacrolimus
14 Lifestyle Versus Ezetimibe Plus Lifestyle in Patients With Non-alcoholic Steatohepatitis Unknown status NCT01950884 Phase 4 Ezetimibe
15 Increasing Cure Rate of Hepatitis C Therapy in Obese Hepatitis C Patients Unknown status NCT00871845 Phase 4 Orlistat
16 Emtricitabine for Prevention of Vertical Transmission of HBV in Chinese Pregnant HBsAg Positive Patients Unknown status NCT02327715 Phase 4 Emtricitabine
17 Emtricitabine for Naive Chinese Pregnant Chronic Hepatitis B Patients Unknown status NCT02327702 Phase 4 Emtricitabine
18 Emtricitabine Plus Adefovir Dipivoxil for Naive Chinese HBV Related Cirrhosis Patients Unknown status NCT02327689 Phase 4 Emtricitabine plus adefovir dipivoxil
19 Magnesium in Liver Cirrhosis Unknown status NCT01894867 Phase 4
20 Entecavir for Chronic Hepatitis B Patients With Persistently Normal ALT Unknown status NCT01833611 Phase 4 Entecavir;placebo
21 Telaprevir in Genotype 3 HCV Unknown status NCT02087111 Phase 4 Telaprevir;40 Kd Pegylated interferon alfa 2a;Ribavirin
22 Development of an Imaging Biomarker for Hepatic Fibrosis Using Gadoxetate Disodium Unknown status NCT01783314 Phase 4
23 Various Insulin Regimens for Diabetic Inpatients With Cirrhosis Trial Unknown status NCT01143948 Phase 4 Glargine & Glulisine;Regular insulin;NPH & regular insulin
24 Secondary Prophylaxis of Hepatic Encephalopathy in Cirrhosis Unknown status NCT01178372 Phase 4 Lactulose;Probiotics(VSL#3)
25 Pegylated-Interferon and Ribavirin Plus Metformin in the Treatment of Chronic HCV Infection and Insulin Resistance Unknown status NCT00370617 Phase 4 metformin
26 Treatment of Liver Cirrhosis Due to Hepatitis B Virus With Fuzheng Huayu and Entecavir Unknown status NCT02241590 Phase 4 Entecavir + Placebo;Entecavir + Fuzheng Huayu Tablet
27 Effect of Liraglutide on Fatty Liver Content and Lipoprotein Metabolism Unknown status NCT02721888 Phase 4 Liraglutide;MRI/ MRS (Magnetic Resonance Imaging /Magnetic Resonance Spectroscopy)
28 Traditional Chinese Medicine Combined With Entecavir to Treat Refractory Liver Fibrosis in Liver Cirrhosis Due to HBV Unknown status NCT02241616 Phase 4 Entecavir+Fuzheng Huayu+TCM Granule
29 Efficacy of Telbivudine With or Without add-on Tenofovir According to Roadmap Strategy Compare With Entecavir Unknown status NCT01588912 Phase 4 Telbivudine;Tenofovir;Entecavir
30 Randomized Comparison of Two Albumin Administration Schedules for Spontaneous Bacterial Peritonitis (SBP) Unknown status NCT00761098 Phase 4 Standard Care;Experimental
31 Trial Comparing the Efficacy, Tolerability and Safety Between Three Arms in Treatment of HCV in Egyptian Population Unknown status NCT01896609 Phase 4 Bon one in Arm 3;Xerovirinc in Arm 2;Ribavirin in Arm 1
32 HIV Persistence and Viral Reservoirs Unknown status NCT01025427 Phase 4 Raltegravir, tenofovir/emtricitabine
33 Safety of Acamprosate for Alcohol Dependence in the Elderly: An Open-Label Study (SAFADIE) Unknown status NCT00655967 Phase 4 Acamprosate (Campral);Acamprosate
34 Rifaximin Versus Lactulose in Renal Failure Unknown status NCT00748904 Phase 4 Rifaximin;Lactulose
35 Erythromycin Treatment for Readthrough of APC Gene Stop Codon Mutations in Familial Adenomatous Polyposis Unknown status NCT02175914 Phase 4 Erythromycin
36 Crossover of Higher Dose Statins in Patients With Low High-density Lipoproteins Cholesterol (HDLc) Unknown status NCT00736463 Phase 4 Simvastatin;Atorvastatin 80 mg
37 Metformin for Weight Control in Adolescents Taking Atypical Antipsychotics Unknown status NCT00845936 Phase 4 Metformin
38 A Pilot Study to Treat Patients With Chronic Hepatitis C Virus (HCV) Genotype 1 and End-Stage Renal Disease (ESRD) Unknown status NCT01731301 Phase 4 Ribavirin;Peginterferon;Boceprevir
39 Trial Comparing Metformin Versus Placebo in Non Alcoholic Steatohepatitis (NASH) Patients Receiving Bariatric Surgery for Obesity Unknown status NCT00134303 Phase 4 Metformin
40 Endoesophageal Cryotherapy For Ablating Barrett's Esophagus and Early Stage Esophageal Cancer Unknown status NCT00628784 Phase 4
41 Complex Imaging Assessment of Steatosis Unknown status NCT02669641 Phase 4
42 TO Compare the Triple Drug Therapy and Dual Therapy . Unknown status NCT02075242 Phase 4 Mycophenolate Mofetil;Tacrolimus
43 A Trial of EVL\GVS Alone vs. EVL\GVS Combined Propranolol Unknown status NCT01298284 Phase 4 propranolol
44 Endoscopic Cyanoacrylate Obliteration vs. Nadolol Treatment in the Prevention of Gastric Variceal Rebleeding Unknown status NCT00567216 Phase 4 Nadolol
45 Rifaximin Predicts the Complications of Decompensated Cirrhosis Unknown status NCT02074280 Phase 4 rifaximin
46 Telbivudine Renoprotective Effect in Patients With the HBV-related Liver Cirrhosis: a Randomized Controlled Trial Unknown status NCT01799486 Phase 4 Telbivudine;Enecavir;Adefovir
47 Telbivudine Renoprotective Effect in Patients With HBV-related Liver Cirrhosis Unknown status NCT01693679 Phase 4 Telbivudine, Lamivudine, Adefovir ,Enecavir
48 RCT of Carvedilol Versus Variceal Band Ligation in the Primary Prophylaxis of Oesophageal Variceal Haemorrhage Unknown status NCT01070641 Phase 4 Carvedilol
49 Echocardiographic Assessment of Intrapulmonary Vasodilatation: Agitated Saline Versus Polygeline Unknown status NCT00343122 Phase 4
50 Effect of Betablocker or Aldosterone Antagonist Therapy on Patients With Liver Cirrhosis Unknown status NCT00332904 Phase 4 propranolol;spironolactone

Search NIH Clinical Center for Liver Disease

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Liver Disease cell therapies at LifeMap Discovery.

Cochrane evidence based reviews: liver diseases

Genetic Tests for Liver Disease

Genetic tests related to Liver Disease:

# Genetic test Affiliating Genes
1 Hepatic Failure 28
2 Abnormality of the Liver 28

Anatomical Context for Liver Disease

MalaCards organs/tissues related to Liver Disease:

38
Liver, Testes, Kidney, T Cells, Bone, Lung, Bone Marrow

Publications for Liver Disease

Articles related to Liver Disease:

(show top 50) (show all 3903)
# Title Authors Year
1
Women and alcoholic liver disease - warning of a silent danger. ( 29443115 )
2018
2
Systematic review: the natural history of alpha-1 antitrypsin deficiency, and associated liver disease. ( 29446109 )
2018
3
Adverse transfusion reactions in patients with liver disease. ( 29446157 )
2018
4
Evaluation of nonalcoholic fatty liver disease using magnetic resonance in obese children and adolescents. ( 29438686 )
2018
5
Statin Use In Cirrhosis from Fatty Liver Disease. ( 29443384 )
2018
6
Assessment of prognostic performance of Albumin-Bilirubin, Child-Pugh, and Model for End-stage Liver Disease scores in patients with liver cirrhosis complicated with acute upper gastrointestinal bleeding. ( 29438135 )
2018
7
Hepatitis A and hepatitis B vaccination coverage among adults with chronic liver disease. ( 29395521 )
2018
8
Liver disease in patients with cystic fibrosis. ( 29438119 )
2018
9
Diagnosis of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: Non-invasive tests are enough. ( 29427494 )
2018
10
Risk factors and metabolic abnormality of patients with non-alcoholic fatty liver disease: Either non-obese or obese Chinese population. ( 29428103 )
2018
11
The protective effect of fish oil lipid emulsions on intestinal failure-associated liver disease in a rat model of short-bowel syndrome. ( 29039050 )
2018
12
Changes in inflammatory factors and prognosis of patients complicated with non-alcoholic fatty liver disease undergoing coronary artery bypass grafting. ( 29434690 )
2018
13
The combination of an HDAC6 inhibitor and a somatostatin receptor agonist synergistically reduces hepato-renal cystogenesis in an animal model of polycystic liver disease. ( 29366679 )
2018
14
Intestinal dysbiosis and permeability: the yin and yang in alcohol dependence and alcoholic liver disease. ( 29352076 )
2018
15
Serine/threonine protein kinase 25 antisense oligonucleotide treatment reverses glucose intolerance, insulin resistance, and nonalcoholic fatty liver disease in mice. ( 29404514 )
2018
16
Editorial: the role of colonic inflammation in the progression of liver disease in patients with primary sclerosing cholangitis. ( 29314124 )
2018
17
Practical Dietary Recommendations for the Prevention and Management of Nonalcoholic Fatty Liver Disease in Adults. ( 29438460 )
2018
18
Sarcopenia and risk of nonalcoholic fatty liver disease: A meta-analysis. ( 29451179 )
2018
19
Quantification of hepatic perfusion and hepatocyte function with dynamic gadoxetic acid-enhanced MR imaging in patients with chronic liver disease. ( 29440620 )
2018
20
PNPLA3: A Determinant of Response to Low-Fructose Diet in Nonalcoholic Fatty Liver Disease. ( 29452087 )
2018
21
Autoimmune liver disease-related autoantibodies in patients with biliary atresia. ( 29391761 )
2018
22
Endoscopic ultrasound-guided fine-needle aspiration of portal vein thrombosis in patients with chronic liver disease and suspicion of hepatocellular carcinoma. ( 29420366 )
2018
23
Validation of simple indexes for nonalcoholic fatty liver disease in western China: a retrospective cross-sectional study. ( 29434074 )
2018
24
Should Giant Cell Hepatitis With Autoimmune Hemolytic Anemia Be Considered a Pediatric Autoimmune Liver Disease? ( 29394216 )
2018
25
A noncoding variant in GANAB explains isolated polycystic liver disease (PCLD) in a large family. ( 29243290 )
2018
26
Non-alcoholic fatty liver disease severity is modulated by transglutaminase type 2. ( 29449533 )
2018
27
Open-label study of ademetionine for the treatment of intrahepatic cholestasis associated with alcoholic liver disease. ( 29431335 )
2018
28
Pharmacotherapies for fatigue in chronic liver disease (CLD): a systematic review and meta-analysis (protocol). ( 29444700 )
2018
29
<i>Helicobacter pylori</i> Infection Is Not Associated with Non-alcoholic Fatty Liver Disease: A Cross-Sectional Study in China. ( 29445363 )
2018
30
Obestatin protects and reverses nonalcoholic fatty liver disease and its associated insulin resistance in rats via inhibition of food intake, enhancing hepatic adiponectin signaling, and blocking ghrelin acylation. ( 29429367 )
2018
31
Impact of liver volume on polycystic liver disease-related symptoms and quality of life. ( 29435317 )
2018
32
Origins of Portal Hypertension in Nonalcoholic Fatty Liver Disease. ( 29368124 )
2018
33
Relationship between diverticulosis and nonalcoholic fatty liver disease in elderly patients. ( 29432700 )
2018
34
Role of genetic and metabolism in non-alcoholic fatty liver disease. ( 29442484 )
2018
35
Diagnosis of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: Why liver biopsy is essential. ( 29427497 )
2018
36
Unexplained chronic liver disease in Ethiopia: a cross-sectional study. ( 29439653 )
2018
37
Abbreviated mpMRI protocol for diffuse liver disease: a practical approach for evaluation and follow-up of NAFLD. ( 29450605 )
2018
38
Liver transplantation in adults with liver disease due to common variable immunodeficiency leads to early recurrent disease and poor outcome. ( 29156507 )
2018
39
Future therapy for non-alcoholic fatty liver disease. ( 29427492 )
2018
40
Editorial: the role of colonic inflammation in the progression of liver disease in primary sclerosing cholangitis-Authors' reply and Letter: the effects of colectomy prior to the diagnosis of primary sclerosing cholangitis on prognosis may have been overestimated. ( 29314129 )
2018
41
End-Stage Liver Disease in Patients with Intracranial Hemorrhage is associated with Increased Mortality: A Cohort Study. ( 29452322 )
2018
42
Mitochondrial Mutations in Cholestatic Liver Disease with Biliary Atresia. ( 29343773 )
2018
43
High Prevalence of Liver Fibrosis Among European Adults with Unknown Liver Disease. A Population-Based Study. ( 29452268 )
2018
44
Associations of hyperuricemia and obesity with remission of nonalcoholic fatty liver disease among Chinese men: A retrospective cohort study. ( 29415050 )
2018
45
Intestinal Microbiome Shifts, Dysbiosis, Inflammation, and Non-alcoholic Fatty Liver Disease. ( 29441049 )
2018
46
Safety of Direct Oral Anticoagulants versus Warfarin in Patients with Chronic Liver Disease and Atrial Fibrillation. ( 29444357 )
2018
47
Pediatric Intestinal Failure-Associated Liver Disease: Challenges in Identifying Clinically Relevant Biomarkers. ( 29443401 )
2018
48
Clinical Outcomes of Metformin Use in Populations With Chronic Kidney Disease, Congestive Heart Failure, or Chronic Liver Disease: A Systematic Review. ( 28055049 )
2017
49
The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement. ( 28521870 )
2017
50
Novel CLDN1 mutation in ichthyosis-hypotrichosis-sclerosing-cholangitis syndrome without signs of liver disease. ( 28906553 )
2017

Variations for Liver Disease

Expression for Liver Disease

Search GEO for disease gene expression data for Liver Disease.

Pathways for Liver Disease

GO Terms for Liver Disease

Cellular components related to Liver Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.65 ADIPOQ AFP ALB F2 GGT1 GPT
2 platelet alpha granule lumen GO:0031093 9.43 ALB HGF SERPINA1
3 intercellular canaliculus GO:0046581 9.16 ABCB11 ABCB4
4 endoplasmic reticulum lumen GO:0005788 9.1 AFP ALB F2 INS PRKCSH SERPINA1
5 extracellular exosome GO:0070062 10.02 ABCB11 ABCB4 ADIPOQ ALB F2 FAH

Biological processes related to Liver Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 regulation of receptor activity GO:0010469 9.72 ADIPOQ F2 HGF INS TNF
2 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.54 ADIPOQ HGF INS
3 negative regulation of lipid catabolic process GO:0050995 9.48 INS TNF
4 regulation of protein secretion GO:0050708 9.46 INS TNF
5 positive regulation of cellular protein metabolic process GO:0032270 9.43 ADIPOQ INS
6 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.43 F2 HGF INS
7 negative regulation of gluconeogenesis GO:0045721 9.4 ADIPOQ INS
8 acute-phase response GO:0006953 9.33 F2 INS SERPINA1
9 glucose metabolic process GO:0006006 9.26 ADIPOQ DLAT INS TNF
10 cellular protein metabolic process